<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581462</url>
  </required_header>
  <id_info>
    <org_study_id>ML29452/PETRARCA/FLOT6</org_study_id>
    <nct_id>NCT02581462</nct_id>
  </id_info>
  <brief_title>FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer</brief_title>
  <acronym>PETRARCA</acronym>
  <official_title>FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of Adenocarcinoma of the Stomach and Gastroesophageal Junction Expressing HER-2. A Phase II/III Trial of the AIO.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Trium Analysis Online GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies provide a strong theoretical rationale for the conduct of a randomized study&#xD;
      evaluating the efficacy and safety of Herceptin and pertuzumab in combination with FLOT in&#xD;
      the perioperative treatment of resectable HER-2 positive adenocarcinoma of the stomach or&#xD;
      GEJ.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, controlled, open-label study including patients with&#xD;
      locally advanced adenocarcinoma of the stomach and GEJ scheduled to receive perioperative&#xD;
      chemotherapy. According to centrally assessed HER-2 status: Patients with HER-2 positive&#xD;
      tumors will receive FLOT +/- Herceptin / pertuzumab.&#xD;
&#xD;
      The scope of the phase II portion of the trial is to evaluate pathological response rates of&#xD;
      either regimen assessed by a centralized pathology and define safety and tolerability.&#xD;
&#xD;
      Patients with locally advanced esophagogastric adenocarcinoma (i.e. cT2 any N or any T&#xD;
      N-positive) with exclusion of distant metastases will be included in this trial.&#xD;
&#xD;
      Patients will be stratified by age (18-69 vs. ≥ 70), tumor site (GEJ vs. gastric) and&#xD;
      clinical stage (T1/2 vs. 3/4 and N- vs. N+) and randomized 1:1 to receive either FLOT (Arm A)&#xD;
      or FLOT/Herceptin/pertuzumab (Arm B).&#xD;
&#xD;
      Arm A (control group) Patients randomized to Arm A will receive 4 pre-operative treatments of&#xD;
      FLOT (Docetaxel 50 mg/m², iv over 2 h; Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h;&#xD;
      Leucovorin 200 mg/m² in 250 ml NaCl 0.9 %, iv over 1 h; 5-FU 2600 mg/m², iv over 24 h) on d1,&#xD;
      d15, d29, d43 of the preoperative treatment phase. Surgery is recommended to occur 4 weeks&#xD;
      after last FLOT (4 weeks after d43 = day 71). Patients will receive 4 additional&#xD;
      post-operative treatments of FLOT on d1, d15, d29, and d43 of the post-operative treatment&#xD;
      phase. Post-operative treatment should start 6 to 8 weeks, but at maximum 12 weeks after&#xD;
      surgery.&#xD;
&#xD;
      Arm B (Herceptin/pertuzumab group) Patients randomized to Arm B will receive the FLOT regimen&#xD;
      identical to Arm A as described above in conjunction with three-weekly Herceptin at 8mg/kg&#xD;
      initial dose (Day 1, loading dose) followed by subsequent doses of Herceptin at 6mg/kg on d22&#xD;
      and d43 and pertuzumab at 840mg on d1, d22, and d43. Surgery is recommended to occur 4 weeks&#xD;
      after last FLOT/Herceptin/pertuzumab dose (4 weeks after d43 = day 71). Patients will receive&#xD;
      3 additional doses of Herceptin and pertuzumab on d1, d22, and d43 of the post-operative&#xD;
      treatment phase, together with the postoperative chemotherapy. Moreover, patients will&#xD;
      receive 11 additional doses of Herceptin and pertuzumab after the end of post-operative FLOT.&#xD;
&#xD;
      In both of the arms, tumor assessments (CT or MRI) are performed before randomization and&#xD;
      prior to surgery and then every 3 months thereafter until progression/relapse, death or end&#xD;
      of follow-up.&#xD;
&#xD;
      During treatment, clinical visits (blood cell counts, detection of toxicity) occur prior to&#xD;
      every treatment dose. Safety of FLOT/Herceptin/pertuzumab will be monitored continuously by&#xD;
      careful monitoring of all adverse events (AEs) and serious adverse events (SAEs) reported.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">July 17, 2020</completion_date>
  <primary_completion_date type="Actual">July 17, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PhaseII: Rate of pathological complete response</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase III: Median Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II/III: R0 resection rate</measure>
    <time_frame>75 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Median Progression Free Survival (PFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II/III: Median Overall Survival</measure>
    <time_frame>3/5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: PK Analysis</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II/III: Subgroup analyses: pathological response according to HER-2 status HER-2 IHC 3+ vs. other cases</measure>
    <time_frame>3/5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II/III: Subgroup analyses: PFS according to HER-2 status HER-2 IHC 3+ vs. other cases</measure>
    <time_frame>3/5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II/III: Subgroup analyses: OS according to HER-2 status HER-2 IHC 3+ vs. other cases</measure>
    <time_frame>3/5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: Pathological Response Rates</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: PFS rates</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: OS rates</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase III: Median OS</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Stomach Cancer</condition>
  <condition>Gastroesophageal Junction Cancer</condition>
  <arm_group>
    <arm_group_label>FLOT alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLOT + Herceptin/Pertuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLOT alone</intervention_name>
    <description>Pre-operative therapy:&#xD;
Docetaxel 50 mg/m², d1, d15, d29, d43&#xD;
Oxaliplatin 85 mg/m², d1, d15, d29, d43&#xD;
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)&#xD;
5-FU 2600 mg/m², d1, d15, d29, d43&#xD;
Surgery is recommended to be scheduled 4 weeks after d43.&#xD;
Post-operative therapy (start 6 to 8 weeks after surgery):&#xD;
Docetaxel 50 mg/m², d1, d15, d29, d43&#xD;
Oxaliplatin 85 mg/m², d1, d15, d29, d43&#xD;
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)&#xD;
5-FU 2600 mg/m², d1, d15, d29, d43</description>
    <arm_group_label>FLOT alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FLOT + Herceptin/Pertuzumab</intervention_name>
    <description>Pre-operative therapy:&#xD;
Herceptin 8/6 mg/kg, d1, d22, d43&#xD;
Pertuzumab 840 mg, d1, d22, d43&#xD;
Docetaxel 50 mg/m², d1, d15, d29, d43&#xD;
Oxaliplatin 85 mg/m², d1, d15, d29, d43&#xD;
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)&#xD;
5-FU 2600 mg/m², d1, d15, d29, d43&#xD;
Surgery is recommended to be scheduled 4 weeks after d43.&#xD;
Post-operative therapy (start 6 to 8 weeks after surgery):&#xD;
Herceptin 8/6 mg/kg, d1, d22, d43&#xD;
Pertuzumab 840 mg, d1, d22, d43&#xD;
Docetaxel 50 mg/m², d1, d15, d29, d43&#xD;
Oxaliplatin 85 mg/m², d1, d15, d29, d43&#xD;
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)&#xD;
5-FU 2600 mg/m², d1, d15, d29, d43.</description>
    <arm_group_label>FLOT + Herceptin/Pertuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of the GEJ (type I-III) or the stomach (uT2,&#xD;
             uT3, uT4, any N category, M0), or any T N+ M0 patient, with the following&#xD;
             specifications:&#xD;
&#xD;
               -  Medical and technical operability&#xD;
&#xD;
               -  Centralized detection of either an adenocarcinoma with HER-2 3+ (IHC) or HER-2 2+&#xD;
                  (IHC) with amplification proven by FISH, SISH or CISH&#xD;
&#xD;
          2. No preceding cytotoxic or targeted therapy&#xD;
&#xD;
          3. No prior partial or complete tumor resection&#xD;
&#xD;
          4. Exclusion of the infiltration of any adjacent organs or structures by CT or MRI&#xD;
&#xD;
          5. Exclusion of distant metastasis by CT or MRI of thorax and abdomen, and bone scan (if&#xD;
             osseous lesions are suspected due to clinical signs)&#xD;
&#xD;
          6. Female and male patients ≥ 18 years. Patients in reproductive age must be willing to&#xD;
             use adequate contraception during the study and for 7 months after the end of&#xD;
             pertuzumab and Herceptin treatment (Appropriate contraception is defined as surgical&#xD;
             sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception&#xD;
             (implantable, patch, oral), and double-barrier methods (any double combination of:&#xD;
             IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)).&#xD;
             Female patients with childbearing potential need to have a negative pregnancy test&#xD;
             within 7 days before study start.&#xD;
&#xD;
          7. ECOG ≤ 2&#xD;
&#xD;
          8. Laparoscopic exclusion of peritoneal carcinomatosis, if suspected clinically&#xD;
&#xD;
          9. Adequate haematological, hepatic and renal function parameters:&#xD;
&#xD;
               -  Leukocytes ≥ 3.000/mm³, platelets ≥ 100.000/mm3&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x upper limit of normal, or GFR &gt; 40 ml/min&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x upper limit of normal, AST and ALT ≤ 3.5 x upper limit of&#xD;
                  normal, alkaline phosphatase ≤ 6 x upper limit of normal&#xD;
&#xD;
         10. LVEF value &gt; 55 %, as assessed by echocardiography&#xD;
&#xD;
         11. Patient able and willing to provide written informed consent and to comply with the&#xD;
             study protocol and with the planned surgical procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with involved retroperitoneal (e.g. para-aortal, paracaval or interaortocaval&#xD;
             lymph nodes) or mesenterial lymph nodes (distant metastasis!)&#xD;
&#xD;
          2. Known hypersensitivity against Herceptin, pertuzumab, 5-FU, leucovorin, oxaliplatin,&#xD;
             or docetaxel&#xD;
&#xD;
          3. Other known contraindications against Herceptin, pertuzumab, 5-FU, leucovorin,&#xD;
             oxaliplatin, or docetaxel&#xD;
&#xD;
          4. Documented history of congestive heart failure of any NYHA, myocardial infarction&#xD;
             within the past 6 months before the first dose of study treatment&#xD;
&#xD;
          5. Clinically significant valvular defect , history of poorly controlled arterial&#xD;
             hypertension (systolic blood pressure &gt; 180 mmHG or diastolic blood pressure &gt; 100&#xD;
             mmHg) or uncontrollable high-risk cardiac arrhythmia (i.e tachycardia with a heart&#xD;
             rate &gt; 100/min at rest), significant ventricular arrhythmia (ventricular tachycardia)&#xD;
             or higher grade atrioventricular-block (second degree AV-block Type 2 (Mobitz2) or&#xD;
             third degree AV-block)&#xD;
&#xD;
          6. Past or current history of other malignancies not curatively treated and without&#xD;
             evidence of disease for more than 5 years, except for curatively treated basal cell&#xD;
             carcinoma of the skin and in situ carcinoma of the cervix&#xD;
&#xD;
          7. Known brain metastases&#xD;
&#xD;
          8. Other severe internal disease or acute infection&#xD;
&#xD;
          9. Peripheral polyneuropathy ≥ NCI Grade II&#xD;
&#xD;
         10. Chronic inflammatory bowel disease&#xD;
&#xD;
         11. Clinically significant active GI bleeding&#xD;
&#xD;
         12. On-treatment participation in another clinical study in the period 30 days prior to&#xD;
             inclusion and during the study&#xD;
&#xD;
         13. Subject pregnant or breast feeding, or planning to become pregnant within 6 months&#xD;
             after the end of treatment.&#xD;
&#xD;
         14. Patients in a closed institution according to an authority or court decision (AMG §&#xD;
             40, Abs. 1 No. 4)&#xD;
&#xD;
         15. Any other concurrent antineoplastic treatment including irradiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Clinical Cancer Research Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

